<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="pegfilgrastim-vs-filgrastim-polarchp-dlbcl-kabasawa-ps1965">
    <meta name="study:title" content="PS1965 - Pegfilgrastim vs Filgrastim for FN Prevention in 1L DLBCL (Pola-R-CHP)">
    <meta name="study:fileName" content="Abstracts/PEGFILGRASTIM-VS-FILGRASTIM-POLARCHP-DLBCL-KABASAWA-PS1965.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="1L">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="Pegfilgrastim,Filgrastim,G-CSF,Polatuzumab Vedotin,ADC,Rituximab,Monoclonal Antibody,Chemotherapy,CIT,Pola-R-CHP">

    <title>PS1965: Pegfilgrastim vs Filgrastim (FN Prevention Pola-R-CHP) (Kabasawa) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PS1965 - Pegfilgrastim vs Filgrastim for FN Prevention (1st Cycle Pola-R-CHP in DLBCL)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996 2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim</h4>
                    <p>N=310 1L DLBCL pts on Pola-R-CHP (Japan RWD). Aim: Compare Pegfilgrastim vs Filgrastim for FN prevention (1st cycle).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M12 2.25c-2.362 0-4.474.924-6.04 2.446a.75.75 0 001.06 1.06A7.501 7.501 0 0112 3.75c2.362 0 4.474.924 6.04 2.446a.75.75 0 101.06-1.06A8.963 8.963 0 0012 2.25zM3.696 7.54a.75.75 0 00-1.06 1.06A8.963 8.963 0 0012 21.75a8.963 8.963 0 009.364-13.15.75.75 0 10-1.06-1.06A7.501 7.501 0 0112 20.25a7.501 7.501 0 01-8.304-12.71zm5.158 7.814a.75.75 0 00-1.061-1.06L6 16.108V13.5a.75.75 0 00-1.5 0v4.5a.75.75 0 00.75.75h4.5a.75.75 0 000-1.5H7.892l1.962-1.963zm6.392-3.188a.75.75 0 00-1.06 1.061L16.108 15H13.5a.75.75 0 000 1.5h4.5a.75.75 0 00.75-.75v-4.5a.75.75 0 00-1.5 0v2.108l-1.962-1.962z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention & Method</h4>
                    <p>Pegfilgrastim (N=141) vs Filgrastim (N=169). Retrospective cohort, IPTW adjustment.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M4.5 19.5a3 3 0 003 3h9a3 3 0 003-3v-1.5a.75.75 0 00-1.5 0V18a1.5 1.5 0 01-1.5 1.5h-9A1.5 1.5 0 016 18v-1.5a.75.75 0 00-1.5 0V19.5zM4.5 8.25A.75.75 0 015.25 9v3.75a.75.75 0 01-1.5 0V9a.75.75 0 01-.75-.75zM19.5 8.25a.75.75 0 00-.75.75v3.75a.75.75 0 001.5 0V9a.75.75 0 00-.75-.75z" /><path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zM8.31 8.47a.75.75 0 00-1.06 1.06L10.94 12l-3.69 3.69a.75.75 0 101.06 1.06L12 13.06l3.69 3.69a.75.75 0 101.06-1.06L13.06 12l3.69-3.69a.75.75 0 10-1.06-1.06L12 10.94 8.31 8.47z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Result: FN Prevention</h4>
                    <p>Adj. FN Incidence: Pegfilgrastim <span class="highlight-value">6.3%</span> vs Filgrastim <span class="highlight-value">17.3%</span> (OR 0.32).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Conclusion</h4>
                    <p>Adj. Hospital Stay: Peg 9d vs Fil 17d. Pegfilgrastim preferred for FN prevention in 1st cycle Pola-R-CHP.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PS1965 - Pegfilgrastim vs. filgrastim for febrile neutropenia prevention in the first cycle of Polatuzumab Vedotin-R-CHP (Pola-R-CHP): a nationwide cohort study in newly diagnosed diffuse large B-cell lymphoma</h1>
            <p class="abstract-sub-header">Nobuyuki Kabasawa, Daisuke Takada, Tetsuji Morishita, Noriko Sasaki, Susumu Kunisawa, Yuichi Imanaka</p>
            <p class="abstract-meta-info mt-2">EHA2025 Congress | Abstract #PS1965 | Poster Presentation | Session: Aggressive Non-Hodgkin lymphoma - Clinical</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>The standard treatment for diffuse large B-cell lymphoma (DLBCL) has been well established.</li>
                        <li>The phase 3 POLARIX trial demonstrated that Pola-R-CHP improved progression-free survival compared to R-CHOP.</li>
                        <li>However, the incidence of febrile neutropenia (FN) was higher in the Pola-R-CHP group than in the R-CHOP group (14.3% vs. 8.0%).</li>
                        <li>No reports have clarified the optimal FN prevention strategy for Pola-R-CHP, including the choice of granulocyte colony-stimulating factor (G-CSF), its administration timing, and duration.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To compare the effectiveness of pegfilgrastim and filgrastim in preventing FN in the first cycle of Pola-R-CHP in newly diagnosed DLBCL patients.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>This retrospective cohort study utilized a Diagnosis Procedure Combination (DPC) database covering over 500 acute care hospitals in Japan.</li>
                        <li>The study included newly diagnosed, untreated DLBCL patients aged ≥18 years who were hospitalized for the first cycle of Pola-R-CHP between August 2022 and March 2024 and received either pegfilgrastim or filgrastim prophylactically.</li>
                        <li>An inverse probability of treatment weighting (IPTW) approach using propensity score analysis was performed to compare FN incidence, adjusting for age, sex, body mass index, cancer stage, Charlson comorbidity index, activities of daily living, initial dose ratio, and prophylactic antibiotic use.</li>
                        <li>Primary endpoint: Incidence of FN. FN was defined as cases requiring broad-spectrum antibiotics initiated on the same day as blood culture collection, from the day after chemotherapy initiation and within 21 days in patients who received G-CSF prophylaxis.</li>
                        <li>Secondary endpoints: In-hospital mortality and length of hospital stay. The study also assessed G-CSF administration timing and duration.</li>
                    </ul>
                    <div class="study-design-schema">
                        <h3 class="schema-title">Pegfilgrastim vs. Filgrastim for FN Prevention with 1st Cycle Pola-R-CHP</h3>
                        <div class="schema-enrollment">
                            <strong>Newly Diagnosed DLBCL Pts (N=310)</strong>
                            <span>(Japanese DPC Database, Aug 2022 - Mar 2024)</span>
                            <span>1st Cycle Pola-R-CHP + Prophylactic G-CSF</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group justify-around">
                            <div class="schema-phase" style="flex-basis: 48%;">
                                <strong>Pegfilgrastim Group (N=141)</strong>
                            </div>
                            <div class="schema-phase" style="flex-basis: 48%;">
                                <strong>Filgrastim Group (N=169)</strong>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>Method: Retrospective Cohort, IPTW Propensity Score Analysis</span>
                           <span>Primary Endpoint: Febrile Neutropenia (FN) Incidence</span>
                           <span>Secondary Endpoints: In-hospital mortality, Length of hospital stay</span>
                        </div>
                    </div>
                </div>
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=310)</h2>
                    <p class="text-sm mb-2">Among 773 DLBCL patients, 310 received G-CSF prophylaxis (pegfilgrastim: 141 [45.5%], filgrastim: 169 [54.5%]). After IPTW adjustment, standardized mean differences for all covariates were &lt;0.1, confirming balance between the groups.</p>
                    <div class="abstract-card mt-4 table-container-card">
                        <h3 class="text-md font-semibold mb-2 text-center" style="color: var(--sobi-dark-blue);">Table 1: Patient Characteristics</h3>
                        <img id="patientCharTableThumbnail" src="image_715bda.jpg" alt="Table 1. Patient Characteristics" class="table-image-thumbnail mx-auto rounded-lg shadow-md">
                        <p class="text-xs text-center mt-2 italic">Table 1 from abstract. Click image to enlarge.</p>
                    </div>
                    <div id="patientCharTableLightbox" class="lightbox">
                        <span class="lightbox-close" id="closePatientCharTableLightbox">&times;</span>
                        <img class="lightbox-content" id="patientCharTableLightboxImage">
                        <div class="lightbox-caption" id="patientCharTableLightboxCaption"></div>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy & Safety Outcomes</h2>
                     <p class="text-sm mb-2 font-semibold">Febrile Neutropenia (FN) Incidence:</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>Unadjusted: Pegfilgrastim 6.3% (9/141) vs. Filgrastim 18.3% (31/169).</li>
                        <li>IPTW Adjusted: Pegfilgrastim 6.3% vs. Filgrastim 17.3% (Odds Ratio [OR]: 0.32, 95% CI: 0.14-0.74).</li>
                    </ul>
                    <div class="chart-container my-4">
                        <svg id="fnIncidenceChart" width="350" height="280"></svg>
                        <div id="fnIncidenceLegend" class="legend"></div>
                    </div>

                    <p class="text-sm mb-2 font-semibold mt-4">Secondary Outcomes:</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>In-hospital Mortality:
                            <ul class="list-circle list-inside ml-4">
                                <li>Pegfilgrastim: 0% (0/141).</li>
                                <li>Filgrastim: 1.8% (8/169)<sup>*</sup>.</li>
                            </ul>
                        </li>
                        <li>Median Length of Hospital Stay (IPTW Adjusted):
                            <ul class="list-circle list-inside ml-4">
                                <li>Pegfilgrastim: 9 days (IQR: 4.5-13.5).</li>
                                <li>Filgrastim: 17 days (IQR: 13.5-20.5) (significantly shorter for pegfilgrastim).</li>
                            </ul>
                        </li>
                    </ul>
                     <p class="text-sm mb-2 font-semibold mt-4">G-CSF Administration:</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Median Day of Initiation: Pegfilgrastim Day 2 (IQR: 2,2) vs. Filgrastim Day 6 (IQR: 4,7) (earlier for pegfilgrastim).</li>
                        <li>Administration Duration: Pegfilgrastim single dose vs. Filgrastim median 7 days (IQR: 6,9).</li>
                    </ul>
                    <p class="text-xs mt-1 footnote-text"><sup>*</sup>Abstract states "eight deaths (8/169, 1.8%)"; 8/169 is ~4.7%, while 1.8% of 169 is ~3. Displaying reported percentage.</p>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>Pegfilgrastim had a lower FN incidence and a shorter hospital stay compared to filgrastim in newly diagnosed DLBCL patients receiving the first cycle of Pola-R-CHP.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>1L, First-Line; ADL, Activities of Daily Living; BMI, Body Mass Index; CCI, Charlson Comorbidity Index; CHEMO, Chemotherapy; CI, Confidence Interval; CIT, Chemoimmunotherapy; DLBCL, Diffuse Large B-Cell Lymphoma; DPC, Diagnosis Procedure Combination; FN, Febrile Neutropenia; G-CSF, Granulocyte Colony-Stimulating Factor; IDR, Initial Dose Ratio; IQR, Interquartile Range; IPTW, Inverse Probability of Treatment Weighting; OR, Odds Ratio; Pola-R-CHP, Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; SMD, Standardized Mean Difference.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Kabasawa N, Takada D, Morishita T, et al. Pegfilgrastim vs. filgrastim for febrile neutropenia prevention in the first cycle of Polatuzumab Vedotin-R-CHP (Pola-R-CHP): a nationwide cohort study in newly diagnosed diffuse large B-cell lymphoma. Abstract #PS1965 presented at the European Hematology Association (EHA) Congress. June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA2025 Congress | Abstract #PS1965 | Abstract Release: 05/14/25 | Presentation: June 14, 2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>
    <script defer src="abstract_features.js"></script>
    <script>
        // Lightbox JavaScript for Patient Characteristics Table
        document.addEventListener('DOMContentLoaded', function() {
            const lightbox = document.getElementById('patientCharTableLightbox');
            const lightboxImg = document.getElementById('patientCharTableLightboxImage');
            const lightboxCaption = document.getElementById('patientCharTableLightboxCaption');
            const thumbnail = document.getElementById('patientCharTableThumbnail');
            const closeBtn = document.getElementById('closePatientCharTableLightbox');

            if (thumbnail) {
                thumbnail.onclick = function(){
                    lightbox.style.display = "block";
                    lightboxImg.src = this.src; // Use thumbnail src for lightbox
                    lightboxCaption.innerHTML = this.alt;
                }
            }

            if (closeBtn) {
                closeBtn.onclick = function() {
                    lightbox.style.display = "none";
                }
            }
            if (lightbox) {
                lightbox.onclick = function(event) {
                    if (event.target === lightbox) { 
                        lightbox.style.display = "none";
                    }
                }
            }
        });

        function drawFnIncidenceChart(containerId, legendContainerId) {
            const chartTitle = "Adjusted FN Incidence (1st Cycle Pola-R-CHP)";
            const chartData = [
                { group: "Pegfilgrastim", value: 6.3 },
                { group: "Filgrastim", value: 17.3 }
            ];
            const pValueText = "OR: 0.32 (95% CI: 0.14-0.74)"; // For display

            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);

            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 350;
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.85, 280);
            }
            
            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height");

            const margin = { top: 50, right: 20, bottom: 60, left: 50 }; // Adjusted bottom margin
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <=0) return;

            const g = svg.append("g")
                .attr("transform", \`translate(\${margin.left},\${margin.top})\`);

            const groups = chartData.map(d => d.group);
            
            const xScale = d3.scaleBand()
                .domain(groups)
                .range([0, chartWidth])
                .padding(0.4);

            const yScale = d3.scaleLinear()
                .domain([0, d3.max(chartData, d => d.value) * 1.2 || 20]) // Dynamic Y based on max value, ensure at least 20
                .range([chartHeight, 0]);

            const colorScale = d3.scaleOrdinal()
                .domain(groups)
                .range(["var(--sobi-teal)", "var(--sobi-orange)"]);

            g.append("g")
                .attr("transform", \`translate(0,\${chartHeight})\`)
                .call(d3.axisBottom(xScale))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px")
                .attr("transform", "translate(0,5)");

            g.append("g")
                .call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d.toFixed(1) + "%"))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px");

            g.append("g")			
                .attr("class", "grid")
                .call(d3.axisLeft(yScale)
                    .ticks(5)
                    .tickSize(-chartWidth)
                    .tickFormat("")
                )
                .selectAll("line")
                .style("stroke", "#e0e0e0")
                .style("stroke-opacity", "0.7");

            g.selectAll(".bar")
                .data(chartData)
                .enter().append("rect")
                  .attr("class", "bar")
                  .attr("x", d => xScale(d.group))
                  .attr("y", d => yScale(d.value))
                  .attr("width", xScale.bandwidth())
                  .attr("height", d => chartHeight - yScale(d.value))
                  .attr("fill", d => colorScale(d.group))
                  .attr("rx", 3).attr("ry", 3);
            
            g.selectAll(".bar-label")
                .data(chartData)
                .enter().append("text")
                .attr("class", "chart-label")
                .attr("x", d => xScale(d.group) + xScale.bandwidth() / 2)
                .attr("y", d => yScale(d.value) - 5) 
                .attr("text-anchor", "middle")
                .style("font-size", "10px")
                .style("fill", "var(--sobi-dark-text)")
                .text(d => \`\${d.value.toFixed(1)}%\`);
            
            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", margin.top / 2)
                .attr("text-anchor", "middle")
                .style("font-size", "14px")
                .style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)")
                .text(chartTitle);
            
            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", chartHeight + margin.top + 35) // Position below x-axis
                .attr("text-anchor", "middle")
                .style("font-size", "10px")
                .style("font-weight", "normal")
                .style("fill", "var(--sobi-dark-text)")
                .text(pValueText);

            const legendData = chartData.map(d => ({
                label: d.group,
                color: colorScale(d.group)
            }));

            const legendItems = legendContainer.selectAll(".legend-item")
                .data(legendData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.label);
        }
        
        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => {
                    clearTimeout(timeout);
                    func(...args);
                };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawFnChart = debounce(() => drawFnIncidenceChart("#fnIncidenceChart", "#fnIncidenceLegend"), 250);
        
        window.addEventListener('resize', debouncedDrawFnChart);
        
        document.addEventListener('DOMContentLoaded', () => {
            debouncedDrawFnChart();
        });
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(debouncedDrawFnChart, 0); 
        }
    </script>
</body>
</html>